In addition, we recently observed that in a NSCLC cell line, nedaplatin activity was less determined by NRF2 (nuclear factor, erythroid 2 like 2) signaling than was cisplatin [26]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.